Search

Your search keyword '"Calafiore, Am"' showing total 20 results
Start Over Author "Calafiore, Am" Database OpenAIRE
20 results on '"Calafiore, Am"'

2. Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair

Author

Paparella, D, Di Mauro, M, Bitton Worms, K, Bolotin, G, Russo, C, Trunfio, S, Scrofani, R, Antona, C, Actis Dato, G, Casabona, R, Colli, A, Gerosa, G, Renzulli, A, Serraino, F, Scrascia, G, Zaccaria, S, De Bonis, M, Taramasso, M, Delgado, L, Tritto, F, Marmo, J, Parolari, A, Myaseodova, V, Villa, E, Troise, G, Nicolini, F, Gherli, T, Whitlock, R, Conte, M, Barili, F, Gelsomino, S, Lorusso, R, Sciatti, E, Marinelli, D, Di Giammarco, G, Calafiore, Am, Sheikh, A, Alfonso, Jj, Glauber, M, Miceli, A, Rotunno, C, Beckerman, Z, Martinelli, L, Lanfranconi, M, Foresti, D, Varone, E, Punta, G, Alfieri, O, Lapenna, E, Ismeno, G, Pulcino, A, Alamanni, F, Dalla Tomba, M, Coletti, G, Vizzardi, Enrico, Lio, A, Solinas, M, Foschi, M, and Giroc, Investigators

Published
2016

3. Functional tricuspid regurgitation: an underestimated issue

Author

Di Mauro, M, Bezante, Gp, Di Baldassarre, A, Clemente, D, Cardinali, A, Acitelli, A, Salerni, S, Penco, Maria, Calafiore, Am, Gallina, S, and Italian Study Group on Valvular Heart Disease Italian Society of Cardiology

Subjects
Heart Valve Prosthesis Implantation, medicine.medical_specialty, Right Ventricular Dysplasia, Tricuspid valve, business.industry, Ventricular Dysfunction, Right, Valvular regurgitation, Atrial fibrillation, medicine.disease, Pulmonary hypertension, Tricuspid Valve Insufficiency, medicine.anatomical_structure, Functional tricuspid regurgitation, Internal medicine, Mitral valve, cardiovascular system, Cardiology, Animals, Humans, Medicine, cardiovascular diseases, Radiology, Systole, Cardiology and Cardiovascular Medicine, business
Abstract

This review article focuses on functional tricuspid regurgitation (FTR) that has long been a neglected and underestimated entity. FTR is defined as leakage of the tricuspid valve during systole in the presence of structurally normal leaflets and chordae. FTR may be secondary to several heart diseases, more commonly mitral valve disease, pulmonary hypertension, atrial fibrillation, cardiomyopathies, right ventricular dysplasia, and idiopathic annular dilatation. The reported prevalence of moderate or greater FTR is roughly 16%, but it rises up to 89% when considering FTR of any grade. According to the recommendations of the European Association of Echocardiography, two-dimensional transthoracic echocardiography (TTE) is the first-line imaging modality for the assessment of valvular regurgitation, whereas three-dimensional TTE may provide additional information in patients with complex valve lesions. Transesophageal echocardiography may be used when TTE results are inconclusive. The natural history of FTR is unfavorable, even in less than severe tricuspid regurgitation. Data from the literature suggest that moderate or greater FTR is a risk factor for worse survival. In addition, FTR of any grade may worsen over time, which makes it reasonable to consider the correction of FTR at an early stage, preferably at the time of mitral valve surgery. Tricuspid valve annuloplasty is the gold standard surgical treatment for FTR and is associated with a recurrence rate, defined as postoperative moderate or severe FTR, ranging from 2.5 to 5.5% at 1-year follow-up.

Published
2013

4. The Italian study on the Mitroflow postoperative results (ISTHMUS): a 20-year,multicentre evaluation of Mitroflow pericardial bioprosthesis

Author

Lorusso, R, Gelsomino, S, De Cicco, G, Vizzardi, Enrico, Faggiano, P, Carella, R, Billè, G, Teodori, G, Caimmi, P, Dato, Ga, Casabona, R, Welter, L, De Paulis, R, Calafiore, Am, Di Mauro, M, Di Credico, G, Leva, C, Messina, A, Villa, E, Troise, G, Borghetti, V, Pardini, A, Medici, D, Sala, A, Citterio, E, Barbone, A, Vitali, E, Tarelli, G, Formica, F, and Paolini, G.

Published
2011

6. The Italian study of the Mitroflow postoperative results (ISTHMUS): a 20-year, multicenter evaluation of Mitroflow pericardial bioprosthesis

Author

ISTHMUS Investigators, Lorusso, R, Gelsomino, S, De Cicco, G, Vizzardi, E, Faggiano, P, Carella, R, Billè, G, Teodori, G, Caimmi, P, Dato, GA, Casabona, R, Welter, L, De Paulis, R, Calafiore, AM, Di Mauro, M, Di Credico, G, Leva, C, Messina, A, Villa, E, Troise, G, Borghetti, V, Pardini, A, Medici, D, Sala, A, Citterio, E, Barbone, A, Vitali, E, Tarelli, G, FORMICA, FRANCESCO, PAOLINI, GIOVANNI, Isthmus, I, Lorusso, R, Gelsomino, S, De Cicco, G, Vizzardi, E, Faggiano, P, Carella, R, Billè, G, Teodori, G, Caimmi, P, Dato, G, Casabona, R, Welter, L, De Paulis, R, Calafiore, A, Di Mauro, M, Di Credico, G, Leva, C, Messina, A, Villa, E, Troise, G, Borghetti, V, Pardini, A, Medici, D, Sala, A, Citterio, E, Barbone, A, Vitali, E, Tarelli, G, Formica, F, and Paolini, G

Subjects
Pulmonary and Respiratory Medicine, Male, Reoperation, medicine.medical_specialty, Pediatrics, medicine.medical_treatment, Aortic Valve Insufficiency, Prosthesis Design, Prosthesis, Interquartile range, medicine, Postoperative results, Endocarditis, Humans, Mitroflow, biologica valve, aortic valve, Coronary Artery Bypass, Aged, Aged, 80 and over, Bioprosthesis, Heart Valve Prosthesis Implantation, business.industry, General Medicine, Aortic Valve Stenosis, medicine.disease, Surgery, Prosthesis Failure, MED/23 - CHIRURGIA CARDIACA, medicine.anatomical_structure, Treatment Outcome, Embolism, Italy, Cardiothoracic surgery, Concomitant, Aortic Valve, Heart Valve Prosthesis, Female, Cardiology and Cardiovascular Medicine, business, Epidemiologic Methods, Pericardium, Artery
Abstract

Objective: A multicentre experience with the Mitroflow pericardial bioprosthesis has been evaluated longitudinally over a 20-year period. Methods: From 1988 through 2008, 1591 patients (mean age, 75.3 ± 6.8 years, and 60.1% female) from 12 centres had a Mitroflow in the aortic position. Concomitant coronary artery bypass was performed in 41.9% (n = 666) of patients, urgency/emergency surgery in 9.5% (n = 152) and replacement of degenerated prosthesis in 2.3% (n = 36). Follow-up (7.447 patient-years) was 99.2% complete. Median follow-up was 61.9 months (interquartile range (IQR) 30.8-90.9 months). The study was carried out following American Association for Thoracic Surgery/Society for Thoracic Surgeons/European Association for Cardio-Thoracic Surgery (AATS/STS/EACTS) Guidelines for reporting valve morbidity and mortality. Results: The early (30-day) mortality was 6.5% (n = 104). Actuarial survival rates at 10, 15 and 18 years were 53%, 34% and 27%, respectively (2.2 patient/year). Re-operation was required in 96 patients (5.9%), of whom 59 patients (3.7%) for structural valve degeneration. Actuarial freedom from prosthetic valve degeneration at 18 years was 65.5% (78% in patients >70 years) with a linearised rate of 1.4 patient/year (0.8 patient/year in patients >70 years). At 18 years, freedom from embolism was 82% (0.9 patient/year), freedom from valve endocarditis was 89% (0.6 patient/year) and freedom from bleeding episodes was 95% (0.2 patient/year), respectively. Conclusions: This independent multicentre study indicates that the Mitroflow pericardial bioprosthesis provides favourable long-term postoperative results with a low rate of valve-related events and need of re-intervention, particularly in patients older than 70 years.

Published
2011

12. Trattamento chirurgico della fibrillazione atriale associata a valvulopatia mitralica. 'Maze Procedure' e chirurgia della mitrale

Author

Alessandrini, F, Santarelli, P, Bellocci, F, Pennestrì, F, Lanza, Ga, Zamparelli, R, Schiavello, R, Marchetti, C, Bartoccioni, S, Glieca, F, Luciani, N, Calafiore, Am, Possati, Gf, LOMBARDO, ANGELO LEONE, DE BONIS, MICHELE, Alessandrini, F, Santarelli, P, Bellocci, F, Pennestrì, F, Lombardo, ANGELO LEONE, Lanza, Ga, Zamparelli, R, Schiavello, R, DE BONIS, Michele, Marchetti, C, Bartoccioni, S, Glieca, F, Luciani, N, Calafiore, Am, and Possati, Gf

Published
1994

13. Results of the 'Maze Procedure' in patients undergoing mitral valve surgery

Author

Alessandrini F, Santarelli P, Lombardo A, Pennestrì F, Glieca F, Luciani N, Bellocci F, Marchetti C, Schiavello R, Bartoccioni S, Calafiore AM, Possati G.F., DE BONIS , MICHELE, Alessandrini, F, Santarelli, P, Lombardo, A, Pennestrì, F, Glieca, F, Luciani, N, DE BONIS, Michele, Bellocci, F, Marchetti, C, Schiavello, R, Bartoccioni, S, Calafiore, Am, and Possati, G. F.

Published
1994

14. 'Maze Procedure' associata a trattamento chirurgico delle valvulopatie mitraliche fibrillanti

Author

Alessandrini F, Santarelli P, Bartoccioni S, Schiavello R, Glieca F, Marchetti C, Calafiore AM, Possati GF Proceedings from the International Workshop '', Amalfi, Italy, 24 25 September 1993, page 319 3.3.7., DE BONIS , MICHELE, Alessandrini, F, Santarelli, P, Bartoccioni, S, Schiavello, R, DE BONIS, Michele, Glieca, F, Marchetti, C, Calafiore, Am, Possati GF Proceedings from the International Workshop, '', Amalfi, Italy, 24 25 September, 1993, and page 319, 3. 3. 7.

Published
1993

15. Total arterial myocardial revascularization

Author

Calafiore Am

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Myocardial revascularization, business.industry, Stomach, Arteries, Epigastric Arteries, Text mining, Treatment Outcome, Internal medicine, Radial Artery, Cardiology, Myocardial Revascularization, Medicine, Humans, Surgery, Mammary Arteries, Cardiology and Cardiovascular Medicine, business, Omentum, Follow-Up Studies
Published
1997

18. [Aneurysms of the membranous septum]

Author

Calafiore, Am, Santarelli, P., Lino, R., Rispoli, Pietro, Liore, L., Possati, F., and Morino, F.

Subjects
Heart Septal Defects, Ventricular, Male, Adolescent, Humans, Female, Heart Aneurysm, Child
Published
1978

19. Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair

Author

Domenico Paparella, Michele Di Mauro, Keren Bitton Worms, Gil Bolotin, Claudio Russo, Salvatore Trunfio, Roberto Scrofani, Carlo Antona, Guglielmo Actis Dato, Riccardo Casabona, Andrea Colli, Gino Gerosa, Attilio Renzulli, Filiberto Serraino, Giuseppe Scrascia, Salvatore Zaccaria, Michele De Bonis, Maurizio Taramasso, Luis Delgado, Francesco Tritto, Joseph Marmo, Alessandro Parolari, Veronika Myaseodova, Emmanuel Villa, Giovanni Troise, Francesco Nicolini, Tiziano Gherli, Richard Whitlock, Manuela Conte, Fabio Barili, Sandro Gelsomino, Roberto Lorusso, Edoardo Sciatti, Daniele Marinelli, Gabriele Di Giammarco, Antonio Maria Calafiore, Azmat Sheikh, Juan Jaime Alfonso, Mattia Glauber, Antonio Miceli, Crescenzia Rotunno, Ziv Beckerman, Luigi Martinelli, Marco Lanfranconi, Davide Foresti, Egidio Varone, Giuseppe Punta, Ottavio Alfieri, Elisabetta Lapenna, Gennaro Ismeno, Achille Pulcino, Francesco Alamanni, Margherita Dalla Tomba, Giuseppe Coletti, Enrico Vizzardi, Antonio Lio, Marco Solinas, Massimiliano Foschi, Nutrition, obésité et risque thrombotique ( NORT ), Institut National de la Recherche Agronomique ( INRA ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), RS: CARIM - R2.12 - Surgical intervention, CTC, MUMC+: MA Med Staf Spec CTC (9), Nutrition, obésité et risque thrombotique (NORT), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Paparella, D, Di Mauro, M, Bitton Worms, K, Bolotin, G, Russo, C, Trunfio, S, Scrofani, R, Antona, C, Actis Dato, G, Casabona, R, Colli, A, Gerosa, G, Renzulli, A, Serraino, F, Scrascia, G, Zaccaria, S, De Bonis, M, Taramasso, M, Delgado, L, Tritto, F, Marmo, J, Parolari, A, Myaseodova, V, Villa, E, Troise, G, Nicolini, F, Gherli, T, Whitlock, R, Conte, M, Barili, F, Gelsomino, S, Lorusso, R, Sciatti, E, Marinelli, D, Di Giammarco, G, Calafiore, Am, Sheikh, A, Alfonso, Jj, Glauber, M, Miceli, A, and Giroc, Investigators

Subjects
Male, Vitamin K, Databases, Factual, analysis, medicine.medical_treatment, Administration, Oral, 030204 cardiovascular system & hematology, antiplatelet, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Cohort Studies, surgery, Postoperative Complications, 0302 clinical medicine, Antithrombotic, anticoagulation, Ultrasonography, Heart Valve Prosthesis Implantation, Incidence, Age Factors, Mitral Valve Insufficiency, Atrial fibrillation, Middle Aged, Vitamin K antagonist, stroke, 3. Good health, Survival Rate, Treatment Outcome, Italy, Platelet aggregation inhibitor, Female, Cardiology and Cardiovascular Medicine, Mitral valve regurgitation, Cohort study, Pulmonary and Respiratory Medicine, Adult, Risk, medicine.medical_specialty, Canada, Patients, complications, medicine.drug_class, Injections, Subcutaneous, Hemorrhage, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, Statistics, Nonparametric, methods, 03 medical and health sciences, mitral valve repair, Sex Factors, Predictive Value of Tests, Thromboembolism, medicine, Humans, bleeding, Surgery, Retrospective Studies, Aged, Mitral valve repair, therapy, business.industry, Anticoagulants, Retrospective cohort study, medicine.disease, mortality, ROC Curve, 030228 respiratory system, Multivariate Analysis, business, Platelet Aggregation Inhibitors, Follow-Up Studies
Abstract

International audience; OBJECTIVE: To verify the rate of thromboembolic and hemorrhagic complications during the first 6 months after mitral valve repair and to assess whether the type of antithrombotic therapy influenced clinical outcome. METHODS: Retrospective data were retrieved from 19 centers. Inclusion criteria were isolated mitral valve repair with ring implantation. Exclusion criteria were ongoing or past atrial fibrillation and any combined intraoperative surgical procedures. The study cohort consisted of 1882 patients (aged 58 +/- 15 years; 36% women), and included 1517 treated with an oral anticoagulant (VKA group) and 365 with antiplatelet drugs (APLT group). Primary efficacy outcome was the incidence of arterial thromboembolic events within 6 months and primary safety outcome was the incidence of major bleeding within 6 months. Propensity matching was performed to obtain 2 comparable cohorts (858 vs 286). RESULTS: No differences were detected for arterial embolic complications in matched cohort (1.6% VKA vs 2.1% APLT; P = .50). Conversely, patients in the APLT group showed lower incidence of major bleeding complications (3.9% vs 0.7%; P = .01). Six-month mortality rate was significantly higher in the VKA group (2.7% vs 0.3%; P = .02). Multivariable analysis in the matched cohort found VKA as independent predictor of major bleeding complications and mortality at 6 months. CONCLUSIONS: Vitamin K antagonist therapy was not superior to antiplatelet therapy to prevent thromboembolic complications after mitral valve repair. Our data suggest that oral anticoagulation may carry a higher bleeding risk compared with antiplatelet therapy, although these results should be confirmed in an adequately powered randomized controlled trial

Published
2016
Full Text
View/download PDF

20. Bipolar radiofrequency maze procedure through a transseptal approach

Author

Stefano Benussi, Roberto Cini, Ottavio Alfieri, Antonio M. Calafiore, Sydney L. Gaynor, Benussi, S, Cini, R, Gaynor, Sl, Alfieri, Ottavio, and Calafiore, Am

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Ablation, Surgery, Clamp, Left atrial, Concomitant, Circulatory system, Atrial Fibrillation, cardiovascular system, medicine, Catheter Ablation, Humans, Bipolar radiofrequency, Cardiac Surgical Procedures, Cardiology and Cardiovascular Medicine, Complication, Stab wound, business, Aged
Abstract

We report how to perform a complete open-heart ablation with bipolar radiofrequency through a transseptal incision. The connecting left atrial lines were performed by inserting one jaw of the clamp through a stab wound in the posterior left atrium, beneath the right inferior pulmonary vein. Twenty-five patients underwent concomitant ablation with the described technique in three different centers. All the left lines were easily performed. No ablation-related complication occurred. At 11 +/- 6 months, 80% of the patients were free from arrhythmias.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results